#398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight loss

June 28, 2026

AI Summary

5 min read

In the early clinical trials of GLP-1 receptor agonists like Ozempic and Wegovy, patients losing substantial weight appeared to be losing lean mass at a roughly 1:1 ratio with fat—meaning for every 10 pounds lost, about five pounds were lean tissue. That observation, which Peter Attia first noticed in his own patients starting around 2014, set off a wave of concern and scientific scrutiny. But as Attia explains in this AMA episode, the story is more nuanced than the early headlines suggested. The real question is not simply how much lean mass is lost, but what kind of lean mass, whether it impairs strength and function, and whether the losses can be mitigated by how patients use the drugs.

What "lean mass" really means—and why DEXA can mislead

Continue reading the full summary in the app — free to try.

Read Full Summary →

Free • No credit card required

Listen to Audio Summary Open in App

Never miss an episode of The Peter Attia Drive

Get every new episode summarized in your inbox — free, ~5 minutes to read.

No spam. Unsubscribe anytime.

What you'll learn

1 (00:10) **Episode Introduction & Topic Overview** - Peter introduces the AMA episode and outlines the key topics: GLP-1 receptor agonists (Ozempic, Wegovy, Zepbound), their impact on muscle loss, lean mass, bone density, strength, and the new drug retatrutide.
2 (02:04) **Historical Context & The Shift in Attention** - Peter and his co-host discuss the evolution of GLP-1 drugs from a niche diabetes treatment to a major weight-loss intervention, and when the clinical community began to notice a problem.
3 (04:06) **Early Clinical Observations of Lean Mass Loss** - Peter describes what he and his colleagues saw in early trials and clinical practice: a surprisingly high proportion of weight lost as lean mass.
4 (05:34) **Reframing the Data: Context and Modifiable Factors** - Peter argues that the clinical trial data must be interpreted with caution because patient counseling on nutrition and exercise can dramatically change outcomes.

+ Full timestamped outline available in the app

Guests on this episode

Peter Attia

Show Notes

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

In this "Ask Me Anything" (AMA) episode, Peter explores the effects of GLP-1 receptor agonists—including drugs such as Ozempic, Wegovy, and Zepbound—with a particular focus on their impact on muscle. He examines how much lean mass people actually lose during treatment and how those changes compare to weight loss achieved through other methods, while explaining why measurements of lean mass on DEXA scans can sometimes be misleading. Peter discusses the effects of these medications on bone mass, fracture risk, strength, and physical function, highlighting why functional outcomes may be more important than body composition metrics alone. He also explores how GLP-1–based therapies affect different fat depots throughout the body, identifies who may be most vulnerable to muscle loss, and outlines practical strategies for preserving muscle and bone health while using these medications. Finally, Peter reviews early insights into retatrutide, a next-generation weight-loss therapy, including what current evidence suggests about its effects on weight loss and muscle mass.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #86 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

The evolution of GLP-1 receptor agonists from diabetes drugs to breakthrough weight-loss therapies [1:45];
Early concerns about lean mass loss with GLP-1 receptor agonists and the limitations of clinical trial data [3:45];
How newer research has changed the understanding of lean mass loss on GLP-1 receptor agonists and why DEXA measurements can misrepresent muscle loss [6: